HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ: LRMR ) with a Buy rating and announces Price Target of $10.